188 related articles for article (PubMed ID: 17397076)
1. Convergent chemical synthesis and crystal structure of a 203 amino acid "covalent dimer" HIV-1 protease enzyme molecule.
Torbeev VY; Kent SB
Angew Chem Int Ed Engl; 2007; 46(10):1667-70. PubMed ID: 17397076
[No Abstract] [Full Text] [Related]
2. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.
Bannwarth L; Kessler A; Pèthe S; Collinet B; Merabet N; Boggetto N; Sicsic S; Reboud-Ravaux M; Ongeri S
J Med Chem; 2006 Jul; 49(15):4657-64. PubMed ID: 16854071
[TBL] [Abstract][Full Text] [Related]
3. Development of low molecular weight HIV-1 protease dimerization inhibitors.
Hwang YS; Chmielewski J
J Med Chem; 2005 Mar; 48(6):2239-42. PubMed ID: 15771466
[TBL] [Abstract][Full Text] [Related]
4. 1.8A X-ray structure of C95M/C1095F double mutant of tethered HIV-1 protease dimer complexed with acetyl pepstatin.
Prashar V; Hosur MV
Biochem Biophys Res Commun; 2004 Oct; 323(4):1229-35. PubMed ID: 15451428
[TBL] [Abstract][Full Text] [Related]
5. Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling.
Frutos S; Rodriguez-Mias RA; Madurga S; Collinet B; Reboud-Ravaux M; Ludevid D; Giralt E
Biopolymers; 2007; 88(2):164-73. PubMed ID: 17236209
[TBL] [Abstract][Full Text] [Related]
6. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
Quéré L; Wenger T; Schramm HJ
Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
[TBL] [Abstract][Full Text] [Related]
7. Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction.
Pillai B; Kannan KK; Bhat SV; Hosur MV
Acta Crystallogr D Biol Crystallogr; 2004 Mar; 60(Pt 3):594-6. PubMed ID: 14993705
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365].
Popov ME; Kashparov IV; Rumsh LD; Popov EM
Bioorg Khim; 1999 Jun; 25(6):418-22. PubMed ID: 10505229
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site.
Torbeev VY; Mandal K; Terechko VA; Kent SB
Bioorg Med Chem Lett; 2008 Aug; 18(16):4554-7. PubMed ID: 18657969
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
[TBL] [Abstract][Full Text] [Related]
12. Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies.
Dohnálek J; Hasek J; Brynda J; Fábry M; Sedlácek J; Konvalinka J; Hradilek M; Soucek M; Adams MJ; Naylor CE
Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():9-11. PubMed ID: 9789742
[No Abstract] [Full Text] [Related]
13. Utilization of L-alpha-nucleobase amino acids (NBAs) as protein engineering tools: construction of NBA-modified HIV-1 protease analogues and enhancement of dimerization induced by nucleobase interaction.
Takahashi T; Yana D; Mihara H
Chembiochem; 2006 May; 7(5):729-32. PubMed ID: 16550624
[No Abstract] [Full Text] [Related]
14. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
[TBL] [Abstract][Full Text] [Related]
15. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
[TBL] [Abstract][Full Text] [Related]
16. A folding inhibitor of the HIV-1 protease.
Broglia RA; Provasi D; Vasile F; Ottolina G; Longhi R; Tiana G
Proteins; 2006 Mar; 62(4):928-33. PubMed ID: 16385559
[TBL] [Abstract][Full Text] [Related]
17. Effects of remote mutation on the autolysis of HIV-1 PR: X-ray and NMR investigations.
Kumar M; Kannan KK; Hosur MV; Bhavesh NS; Chatterjee A; Mittal R; Hosur RV
Biochem Biophys Res Commun; 2002 Jun; 294(2):395-401. PubMed ID: 12051725
[TBL] [Abstract][Full Text] [Related]
18. [Kynostatin (KNI)-272--a rationally designed tripeptide inhibitor of HIV protease].
Kiso Y
Nihon Rinsho; 1993 Sep; 51 Suppl():139-45. PubMed ID: 8271377
[No Abstract] [Full Text] [Related]
19. Modular total chemical synthesis of a human immunodeficiency virus type 1 protease.
Johnson EC; Malito E; Shen Y; Rich D; Tang WJ; Kent SB
J Am Chem Soc; 2007 Sep; 129(37):11480-90. PubMed ID: 17705484
[TBL] [Abstract][Full Text] [Related]
20. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
